4-[(2S,3S)-3-hydroxy-2-isopropylpyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 4-[(2S,3S)-3-hydroxy-2-isopropylpyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
• 英文别名: 4-[(2S,3S)-3-hydroxy-2-propan-2-ylpyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
• 化学式: C₁₅H₁₇F₃N₂O
• 分子量: 298.308
• InChiKey: RTUJBFLNMSYPJW-KBPBESRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  47.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  benzyl (2S,3S)-3-([tert-butyl(dimethyl)silyl]oxy)-2-isopropylpyrrolidine-1-carboxylate 、 4-氟-2-(三氟甲基)苯甲腈 在 palladium 10% on activated carbon 氢气 、 lithium carbonate 、 四丁基氟化铵 、 水 作用下， 以 甲醇 、 二甲基亚砜 为溶剂， 20.0~100.0 ℃ 、101.33 kPa 条件下， 反应 21.0h， 生成 4-[(2S,3S)-3-hydroxy-2-isopropylpyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
  参考文献：
  名称：

  WO2007/15567

  摘要：

  公开号：

文献信息

• CYCLIC AMINE COMPOUND
  申请人：Hasuoka Atsushi

  公开号：US20100087506A1

  公开（公告）日：2010-04-08

  Provision of a compound having a superior androgen receptor regulating action. A compound represented by the formula (I) wherein R 1 is a hydrogen atom, a halogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom or a group via a sulfur atom; R 2 is a hydrogen atom, a halogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom or a group via a sulfur atom; R 3 is an electron-withdrawing group; R 4 is a hydrogen atom, a halogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom or a group via a sulfur atom; R 5 is a hydrogen atom, a halogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom or a group via a sulfur atom; R 6 is a hydrogen atom, a halogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom or a group via a sulfur atom; R 7 is alkyl optionally having substituent(s); R 8 is a hydrogen atom, alkyl optionally having substituent(s), alkenyl optionally having substituent(s) or cycloalkyl optionally having substituent(s); R 9 is a group via an oxygen atom; and ring A is a 5- or 6-membered ring optionally having substituent(s) other than R 6 to R 9 (excluding 2-chloro-4-[(2S,3S)-3-hydroxy-2-methylpyrrolidin-1-yl]-3-methylbenzonitrile, 2-chloro-4-[(2S,3S)-3-hydroxy-2-methylpyrrolidin-1-yl]benzonitrile, 4-[(2S,3S)-3-hydroxy-2-methylpyrrolidin-1-yl]benzonitrile, 2-chloro-4-[(2S,3S)-3-hydroxy-2-methylpyrrolidin-1-yl]-5-methylbenzonitrile, 2-chloro-3-ethyl-4-[(2S,3S)-3-hydroxy-2-methylpyrrolidin-1-yl]benzonitrile, 4-[(2S,3S)-3-hydroxy-2-methylpyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile, 2,3-dichloro-4-[(2S,3S)-3-hydroxy-2-methylpyrrolidin-1-yl]-5-methylbenzonitrile, 2,3-dichloro-4-[(2S,3S)-3-hydroxy-2-methylpyrrolidin-1-yl]benzonitrile, 4-[(2S,3S)-3-hydroxy-2-methylpyrrolidin-1-yl]-3-(trifluoromethyl)benzonitrile, 4-[(2S,3S)-3-hydroxy-2-isopropylpyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile, 4-[(2S,3R)-3-hydroxy-2-isopropylpyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile, and 2-chloro-4-[(2S)-3-hydroxy-2-methylpiperidin-1-yl]benzonitrile), or a salt thereof.

  提供具有优良雄激素受体调节作用的化合物。化合物由公式(I)表示，其中R1为氢原子、卤素原子、通过碳原子、氮原子、氧原子或硫原子连接的基团; R2为氢原子、卤素原子、通过碳原子、氮原子、氧原子或硫原子连接的基团; R3为电子吸引基团; R4为氢原子、卤素原子、通过碳原子、氮原子、氧原子或硫原子连接的基团; R5为氢原子、卤素原子、通过碳原子、氮原子、氧原子或硫原子连接的基团; R6为氢原子、卤素原子、通过碳原子、氮原子、氧原子或硫原子连接的基团; R7为可选带有取代基的烷基; R8为氢原子、可选带有取代基的烷基、烯基或环烷基; R9为通过氧原子连接的基团; 环A为5-或6-成员环，可选带有R6到R9之外的取代基团（不包括2-氯-4-[(2S,3S)-3-羟基-2-甲基吡咯烷-1-基]-3-甲基苯甲腈、2-氯-4-[(2S,3S)-3-羟基-2-甲基吡咯烷-1-基]苯甲腈、4-[(2S,3S)-3-羟基-2-甲基吡咯烷-1-基]苯甲腈、2-氯-4-[(2S,3S)-3-羟基-2-甲基吡咯烷-1-基]-5-甲基苯甲腈、2-氯-3-乙基-4-[(2S,3S)-3-羟基-2-甲基吡咯烷-1-基]苯甲腈、4-[(2S,3S)-3-羟基-2-甲基吡咯烷-1-基]-2-(三氟甲基)苯甲腈、2,3-二氯-4-[(2S,3S)-3-羟基-2-甲基吡咯烷-1-基]-5-甲基苯甲腈、2,3-二氯-4-[(2S,3S)-3-羟基-2-甲基吡咯烷-1-基]苯甲腈、4-[(2S,3S)-3-羟基-2-甲基吡咯烷-1-基]-3-(三氟甲基)苯甲腈、4-[(2S,3S)-3-羟基-2-异丙基吡咯烷-1-基]-2-(三氟甲基)苯甲腈、4-[(2S,3R)-3-羟基-2-异丙基吡咯烷-1-基]-2-(三氟甲基)苯甲腈和2-氯-4-[(2S)-3-羟基-2-甲基哌啶-1-基]苯甲腈）或其盐。
• Cyclic amine compound
  申请人：Yamamoto Satoshi

  公开号：US20100152236A1

  公开（公告）日：2010-06-17

  A compound represented by the formula (I) wherein ring A is a 5- to 8-membered ring optionally having further substituent(s) other than R 6 , R 7 and R 8 , R 1 is an electron-withdrawing group, R 2 , R 3 , R 4 and R 5 are each independently a hydrogen atom, a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, R 6 is a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, R 7 is a cyano group, a nitro group, an acyl group optionally having substituent(s), an optionally esterified or amidated carboxyl group or a hydrocarbon group optionally having substituent(s), or R 6 and R 7 optionally form, together with the carbon atom bonded thereto, a ring optionally having substituent(s), and R 8 is a hydrogen atom, a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, or a salt thereof has a superior action as an androgen receptor modulator, and is useful for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia, osteoporosis and the like.

  化合物的化学式为（I），其中环A是一个5到8个成员的环，可以选择性地具有除R6、R7和R8以外的其他取代基，R1是一个电子吸引基团，R2、R3、R4和R5分别是氢原子、卤素原子、通过碳原子键合的基团、通过氮原子键合的基团、通过氧原子键合的基团或通过硫原子键合的基团，R6是卤素原子、通过碳原子键合的基团、通过氮原子键合的基团、通过氧原子键合的基团或通过硫原子键合的基团，R7是氰基、硝基、可选择具有取代基的酰基、可选择酯化或酰胺化的羧基或可选择具有取代基的碳氢基团，或R6和R7可选择地与其键合的碳原子一起形成一个可选择具有取代基的环，R8是氢原子、卤素原子、通过碳原子键合的基团、通过氮原子键合的基团、通过氧原子键合的基团或通过硫原子键合的基团，或其盐具有卓越的雄激素受体调节剂作用，并且用于预防或治疗性腺机能减退、男性更年期障碍、虚弱、消瘦、骨质疏松等。
• Cyclic amine compound as androgen receptor modulator
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2098507B1

  公开（公告）日：2014-11-12
• US8013008B2
  申请人：——

  公开号：US8013008B2

  公开（公告）日：2011-09-06
• US8592452B2
  申请人：——

  公开号：US8592452B2

  公开（公告）日：2013-11-26